title: Cardiac gene therapy.
abstract: Heart failure is a chronic progressive disorder in which frequent and recurrent hospitalizations are associated with high mortality and morbidity. The incidence and the prevalence of this disease will increase with the increase in the number of the aging population of the United States. Understanding the molecular pathology and pathophysiology of this disease will uncover novel targets and therapies that can restore the function or attenuate the damage of malfunctioning cardiomyocytes by gene therapy that becomes an interesting and a promising field for the treatment of heart failure as well as other diseases in the future. Of equal importance are developing vectors and delivery methods that can efficiently transduce most of the cardiomyocytes that can offer a long-term expression and that can escape the host immune response. Recombinant adeno-associated virus vectors have the potential to become a promising novel therapeutic vehicles for molecular medicine in the future.
authors.affiliation: Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York 10029, USA.
authors.forename: Antoine H
authors.initials: AH
authors.lastname: Chaanine
authors.forename: Jill
authors.initials: J
authors.lastname: Kalman
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Hajjar
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006333:Heart Failure / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D009200:Myocardial Contraction / Q000235:genetics; D032383:Myocytes, Cardiac / Q000378:metabolism* / Q000473:pathology; D020127:Recovery of Function; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000235:genetics; D014780:Viruses / Q000235:genetics